LAMPRENE Drug Patent Profile
✉ Email this page to a colleague
When do Lamprene patents expire, and what generic alternatives are available?
Lamprene is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in LAMPRENE is clofazimine. There are five drug master file entries for this compound. Additional details are available on the clofazimine profile page.
Summary for LAMPRENE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 104 |
Clinical Trials: | 12 |
Patent Applications: | 5,360 |
Formulation / Manufacturing: | see details |
DailyMed Link: | LAMPRENE at DailyMed |
Recent Clinical Trials for LAMPRENE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Radboud University Medical Center | Phase 2 |
Novartis Pharmaceuticals | Phase 2 |
Harvard Medical School | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for LAMPRENE
US Patents and Regulatory Information for LAMPRENE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | LAMPRENE | clofazimine | CAPSULE;ORAL | 019500-002 | Dec 15, 1986 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Novartis | LAMPRENE | clofazimine | CAPSULE;ORAL | 019500-001 | Dec 15, 1986 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |